Category Archives: healthcare

Showing Patients the Bigger Mobile Health Picture

To understand just how far mobile and digital technology can truly influence progress in global healthcare, we first need to form the foundation of the discussion with a few rudimentary facts. Clinical research (“a branch of medical science in human beings”) is critical to healthcare. All patients are human beings. All stakeholders are current or […]
Also posted in Technology | Tagged , , | Leave a comment

Market Access in Ukraine

by Lana Sinichkina  and Leonid Cherniavskyi. On September 16, 2014, the Ukrainian and European parliaments ratified the EU–Ukraine Association Agreement (AA), providing for harmonization of many spheres of Ukrainian legislation with EU policy. In line with the signed AA, the government has adopted a detailed implementation plan, which endorses for preparation and approval by the […]
Also posted in Europe, Global, Guest Blog, Op-Ed, pricing, Regulatory | Tagged , , , | Leave a comment

NIH Invests in Biomedical Big Data

The National Institutes of Health (NIH) announced yesterday that it is issuing nearly $32 million in grants for the development of strategies to analyze and leverage biomedical data sets.  The grants are part of NIH’s Big Data to Knowledge (BD2K) initiative, launched in December 2013. BD2K is funded from all 27 NIH institutes and centers, as […]
Also posted in Strategy, Technology | Tagged , , | Leave a comment

AMCP Talk Pricing of Specialty Pharma Spurred by Sovaldi

Starting off this week’s Academy of Managed Care Pharmacy (AMCP) meeting in Boston, experts including patient access advocates, pharma and payer representatives came together for this year’s symposium entitled “Specialty Pharmacy and Patient Care: Are We at a Tipping Point?”
Also posted in Market Access, pricing | Tagged , , , , , , , | Leave a comment

Healthcare Nonprofit Bans Genentech Reps

By Randi Hernandez, Pharmaceutical Technology. After a change in distribution strategy at Genentech, Ascension Health has prohibited sales representatives from the drug maker to solicit physicians at Ascension’s 1900 sites of care around the country. The ban is the result of a supply-chain move that routes three infused cancer medications—Avastin (bevacizumab), Rituxan (rituximab), and Herceptin […]
Also posted in Guest Blog, Sales | Tagged , , | Leave a comment
  • Categories

  • Meta